The description of a so-called cytokine storm in patients with COVID-19 has prompted
consideration of anti-cytokine therapies, particularly interleukin-6 antagonists. However …

Introduction The coronavirus pandemic has affected more than 20 million people so far.
Elevated cytokines and suppressed immune responses have been hypothesized to set off a …

Purpose Cytokine storm, an uncontrolled overproduction of inflammatory cytokines
contributing to an aberrant systemic inflammatory response, is a major pathological feature …

Background Evidence links COVID-19 severity to hyper-inflammation. Treatment with
tocilizumab, a monoclonal antibody directed against the interleukin-6 (IL-6) receptor, was …

Summary Coronavirus disease 2019 (COVID‐19) is a clinical syndrome caused by the
severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) virus. Patients can be …

Coronaviruses may activate dysregulated host immune responses. As exploratory studies
have suggested that interleukin‐6 (IL‐6) levels are elevated in cases of complicated Covid …

Background Markedly elevated levels of proinflammatory cytokines and defective type-I
interferon responses were reported in patients with coronavirus disease 2019 (COVID-19) …

Objective To delineate the characteristics and clinical significance of plasma inflammatory
cytokines altered in COVID-19. Design Retrospective, single-centre cohort study. Setting …

The dysregulated release of cytokines has been identified as one of the key factors behind
poorer outcomes in COVID-19. This “cytokine storm” produces an excessive inflammatory …

The identification of elevated IL-6 levels in patients with severe COVID-19 led to the rapid
development of clinical trials targeting this cytokine. Overall, these trials do not support the …